Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease

BACKGROUND: As the patents of originator biologics are expiring, biosimilar versions are becoming available for the treatment of inflammatory bowel disease (IBD). However, published switch studies of the first infliximab biosimilar, CT-P13, have delivered ambiguous results that could be interpreted...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergqvist, Viktoria, Kadivar, Mohammad, Molin, Daniel, Angelison, Leif, Hammarlund, Per, Olin, Marie, Torp, Jörgen, Grip, Olof, Nilson, Stefan, Hertervig, Erik, Lillienau, Jan, Marsal, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187418/
https://www.ncbi.nlm.nih.gov/pubmed/30344642
http://dx.doi.org/10.1177/1756284818801244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187418/
https://www.ncbi.nlm.nih.gov/pubmed/30344642
http://dx.doi.org/10.1177/1756284818801244

Ejemplares similares